Who are ANI Pharmaceuticals, Inc.'s main suppliers?

ANI Pharmaceuticals, Inc. (ANIP) key suppliers include: TRUIST-BANK, Emmaus Life Sciences, Inc., EyePoint, Inc.. View the full supplier network at chainsifter.com/chain/ANIP.

Who are ANI Pharmaceuticals, Inc.'s major customers?

ANI Pharmaceuticals, Inc. (ANIP) key customers include: HARMONY-BIOSCIENCES, CUSTOMER-1, CUSTOMER-2, CUSTOMER-3, CUSTOMER-4 and 2 more. View the full customer network at chainsifter.com/chain/ANIP.

What sector is ANI Pharmaceuticals, Inc. in?

ANI Pharmaceuticals, Inc. (ANIP) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

ANIP Supply Chain: ANI Pharmaceuticals, Inc. Supplier List & 12 Relationships

3Suppliers

7Customers

2Debt Items

10Related Chains

ANI Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
TRUIST-BANK	TRUIST-BANK	80%	the Company, as borrower, entered into a credit agreement with Truist Bank and other lenders
EMMA	Emmaus Life Sciences, Inc.	72%	Reciprocal relationship from EMMA graph: these uncertainties. We are dependent on the commercial success of our only product, Endari®. Our ability to become profitable will depend upon the commercial…
EYPT	EyePoint, Inc.	72%	Reciprocal relationship from EYPT graph: Reciprocal relationship from ANIP graph: Reciprocal relationship from EYPT graph: Reciprocal relationship from ANIP graph: Reciprocal relationship from EYPT g…

ANI Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
HARMONY-BIOSCIENCES	HARMONY-BIOSCIENCES	92%	Out-licensed intellectual property to Harmony Biosciences in January 2026
CUSTOMER-1	CUSTOMER-1	90%	Customer 1 accounted for 17% of net revenues during the three months ended March 31, 2026
CUSTOMER-2	CUSTOMER-2	90%	Customer 2 accounted for 10% of net revenues during the three months ended March 31, 2026
CUSTOMER-3	CUSTOMER-3	90%	Customer 3 accounted for 16% of net revenues during the three months ended March 31, 2026
CUSTOMER-4	CUSTOMER-4	90%	Customer 4 accounted for 18% of net revenues during the three months ended March 31, 2026
EMMA	Emmaus Life Sciences, Inc.	72%	Reciprocal relationship from EMMA graph: these uncertainties. We are dependent on the commercial success of our only product, Endari®. Our ability to become profitable will depend upon the commercial…
EYPT	EyePoint, Inc.	72%	Reciprocal relationship from EYPT graph: financial statements. It is important that the discussion of our operating results that follows be read in conjunction with the critical accounting policies d…

ANI Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ANIP-DEBT	Debt stack $630.2M	90%	Market cache reports total debt of $630.2M.
ANIP-DEBT-7763	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.

ANI Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for ANI Pharmaceuticals, Inc..

ANI Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
ANIP-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 282 tracked holders.

ANI Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
EMMA	Emmaus Life Sciences, Inc.	100.00	1	['customer', 'supplier']
OCUL	Ocular Therapeutix, Inc.	100.00	2
BMY	Bristol-Myers Squibb Company	50.00	2
BMYMP	Bristol-Myers Squibb Co	50.00	2
MCK	McKesson Corporation	50.00	2
NVSEF	Novartis AG	50.00	2
TELCON	TELCON	50.00	2
CAH	Cardinal Health, Inc.	50.00	2
CVS	CVS Health Corporation	50.00	2
EYPT	EyePoint, Inc.	36.29	1	['customer', 'supplier']

ANI Pharmaceuticals, Inc. Supply Chain